全文获取类型
收费全文 | 3389篇 |
免费 | 207篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 108篇 |
妇产科学 | 80篇 |
基础医学 | 476篇 |
口腔科学 | 34篇 |
临床医学 | 297篇 |
内科学 | 964篇 |
皮肤病学 | 63篇 |
神经病学 | 448篇 |
特种医学 | 71篇 |
外科学 | 279篇 |
综合类 | 6篇 |
预防医学 | 162篇 |
眼科学 | 62篇 |
药学 | 223篇 |
中国医学 | 4篇 |
肿瘤学 | 346篇 |
出版年
2024年 | 10篇 |
2023年 | 55篇 |
2022年 | 122篇 |
2021年 | 188篇 |
2020年 | 119篇 |
2019年 | 139篇 |
2018年 | 146篇 |
2017年 | 87篇 |
2016年 | 116篇 |
2015年 | 154篇 |
2014年 | 155篇 |
2013年 | 188篇 |
2012年 | 316篇 |
2011年 | 325篇 |
2010年 | 175篇 |
2009年 | 163篇 |
2008年 | 222篇 |
2007年 | 184篇 |
2006年 | 174篇 |
2005年 | 132篇 |
2004年 | 124篇 |
2003年 | 120篇 |
2002年 | 95篇 |
2001年 | 26篇 |
2000年 | 12篇 |
1999年 | 13篇 |
1998年 | 18篇 |
1997年 | 4篇 |
1996年 | 6篇 |
1995年 | 7篇 |
1994年 | 4篇 |
1993年 | 7篇 |
1992年 | 9篇 |
1991年 | 5篇 |
1989年 | 4篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1984年 | 3篇 |
1983年 | 1篇 |
1978年 | 2篇 |
排序方式: 共有3636条查询结果,搜索用时 46 毫秒
1.
2.
Borrelli Enrico Grosso Domenico Vella Giovanna Sacconi Riccardo Battista Marco Querques Lea Zucchiatti Ilaria Prascina Francesco Bandello Francesco Querques Giuseppe 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2020,258(12):2621-2628
Graefe's Archive for Clinical and Experimental Ophthalmology - To estimate the impact of delayed care during the coronavirus disease 2019 (COVID-19) pandemic on the outcomes of patients with... 相似文献
3.
Giuseppe Derosa Arrigo F G Cicero Angela D'Angelo Pietro D Ragonesi Leonardina Ciccarelli Mario N Piccinni Fabio Pricolo Sibilla A T Salvadeo Ilaria Ferrari Alessia Gravina Roberto Fogari 《Hypertension research》2006,29(11):849-856
The aim of our study was to investigate the metabolic effect of telmisartan and irbesartan in subjects treated with rosiglitazone, a well-known insulin-sensitizing drug, in order to clarify the direct metabolic effects of the two former drugs. Patients were enrolled, evaluated, and followed at 3 Italian centers. We evaluated 188 type 2 diabetic patients with metabolic syndrome (94 males and 94 females in total; 49 males and 46 females, aged 56+/-5, treated with telmisartan; and 45 males and 48 females, aged 55+/-4, treated with irbesartan). All had been diabetic for at least 6 months, and glycemic control by the maximum tolerated dietary changes and maximum tolerated dose of oral hypoglycemic agents had been attempted and failed in all cases. All patients took a fixed dose of rosiglitazone, 4 mg/day. We administered telmisartan (40 mg/day) or irbesartan (150 mg/day) in a randomized, controlled, double-blind clinical manner. We evaluated body mass index (BMI), glycemic control (HbA1c fasting plasma glucose and insulin levels [FPG, and FPI, respectively], and homeostasis model assessment [HOMA] index), lipid profile (total cholesterol [TC], low density lipoprotein-cholesterol [LDL-C], high density lipoprotein-cholesterol [HDL-C], and triglycerides [TG]), systolic and diastolic blood pressure (SBP and DBP), tumor necrosis factor-alpha (TNF-alpha), and leptin during the 12 months of this treatment. No BMI change was observed after 6 or 12 months in either group. Significant decreases in HbAlc and FPG were observed after 6 months in the telmisartan group, and after 12 months in both groups. The decrease in HbA1c and FPG at 12 months was statistically significant only in the telmisartan group. A significant decrease in FPI was observed at 12 months in both groups, and this decrease was significantly greater in the telmisartan group. Significant decreases in the HOMA index were observed at 6 and 12 months in both groups, and the decrease in the HOMA index after 12 months was significantly greater in the telmisartan group than in the irbesartan group. Significant changes in SBP, DBP, TC, and LDL-C were observed after 6 and 12 months in both groups. Significant decreases in TNF-alpha and leptin levels were observed after 6 months in the telmisartan group, and after 12 months in both groups. In conclusion, in this study of patients with type 2 diabetes mellitus and metabolic syndrome, telmisartan seemed to result in a greater improvement in glycemic and lipid control and metabolic parameters related to metabolic syndrome compared to irbesartan. These observed metabolic effects of different angiotensin type 1 receptor blockers could be relevant when choosing a therapy to correct metabolic derangement of patients affected by metabolic syndrome and diabetes. 相似文献
4.
Antinori Andrea Cingolani Antonella Lorenzini Patrizia Giancola Maria Letizia Uccella Ilaria Bossolasco Simona Grisetti Susanna Moretti Francesca Vigo Beniamino Bongiovanni Marco Del Grosso Bruno Arcidiacono Maria Irene Fibbia Giovanni Carlo Mena Maurizio Finazzi Maria Grazia Guaraldi Giovanni Ammassari Adriana Monforte Antonella dArminio Cinque Paola De Luca Andrea 《Journal of neurovirology》2003,9(1):47-53
Human immunodeficiency virus (HIV)-associated progressive multifocal leukoencephalopathy (PML) remains a relevant clinical problem even in the era of highly active antiretroviral therapy (HAART). Aims of the study were to analyze clinical and treatment-related features and the survival probability of PML patients observed within the Italian Registry Investigative Neuro AIDS (IRINA) during a 29-month period of HAART. Intravenous drug use, the presence of focal signs, and the involvement of white matter at neuroradiology increased the risk of having PML. A reduced probability of PML was observed when meningeal signs were reported. Patients starting HAART at PML diagnosis and previously naïve for antiretrovirals showed significantly higher 1-year probability of survival (.58), compared to those continuing HAART (.24), or never receiving HAART (.00). Higher CD4 cell count were associated with a higher survival probability (.45). At multivariate analysis, a younger age, higher CD4, starting HAART at PML diagnosis, the absence of previous acquired immunodeficiency syndrome (AIDS)-defining events, and the absence of a severe neurologic impairment were all associated with a reduced hazard of death. The use of cidofovir showed a trend towards a reduced risk of death. 相似文献
5.
6.
Cinzia Bressi Cesare Maria Cornaggia Massimiliano Beghi Matteo Porcellana Ilaria Ida Iandoli Giordano Invernizzi 《Seizure》2007,16(5):417-423
PURPOSE: To verify the emotional components expressed by the relatives of adult patients with a diagnosis of epilepsy, and whether they are related to adjustment to the illness and the course of the illness over time. METHODS: We studied a consecutive sample of 43 outpatients suffering from epilepsy and 43 key relatives using the Camberwell Family Interview (CFI), with the expressed emotion (EE) of the relatives being rated at baseline (T0). EE refers to a construct representing some key aspects of interpersonal relationships: the relatives were assigned to the high-EE group if they scored 3 or more on the emotional over involvement (EOI) scale, or showed hostility, or made 6 or more critical comments. The patients were clinically evaluated at baseline and for 1 year of appropriate treatment by an epileptologist who was blinded to the EE ratings. They also completed STAI XI, STAI X2 and Beck's Depression Inventory at baseline. RESULTS: Twenty-six relatives (60%) were rated as showing a high degree of EE. In the 12-month follow-up study, high EE and high EOI were found to be associated with a significantly higher seizure frequency than that recorded for the patients living in low-EE households (p<0.05). The patients from households assessed as reflecting a high degree of criticism showed poor drug compliance (p<0.01), whereas those with relatives assessed as having a high degree of warmth showed better clinical and pharmacological compliance (p<0.01). High family criticism scores also correlated with higher study entry levels of depression (p<0.05) and trait and state anxiety (p<0.05) among the patients. CONCLUSIONS: The study findings highlight the impact of particular components of the family emotional climate on the clinical course and psychological adjustment of patients with epilepsy. 相似文献
7.
Ilaria Capua Calogero Terregino Giovanni Cattoli Franco Mutinelli J.F. Rodriguez 《Avian pathology》2003,32(1):47-55
The present paper reports of the development and validation of a control strategy for avian influenza infections in poultry. The "DIVA" (Differentiating Infected from Vaccinated Animals) strategy is based on the use of an inactivated oil emulsion vaccine containing the same haemagglutinin (H) subtype as the challenge virus, but a different neuraminidase (N). The possibility of using the heterologous N subtype, to differentiate between vaccinated and naturally infected birds, was investigated through the development of an "ad hoc" serological test based on the detection of specific anti-N1 antibodies. This was achieved using a baculovirus expressing a recombinant N1 protein. The A/ck/Pakistan/H7N3 virus was used as a vaccine and birds were challenged with the HPAI A/ty/Italy/4580/V99/H7N1 strain. The homologous H group ensured a clinical protection of 93% regardless of the vaccination scheme used, and was able to prevent viraemia and muscle colonization in the clinically healthy challenged birds. However, it was not able to prevent viral shedding. The "ad hoc" serological assay was developed as an indirect immunofluorescence test, and was validated using 608 field sera, and showed an "almost perfect agreement" (Kappa value) with the HI test, with relative sensitivity and specificity values of 98.1 and 95.7, respectively. The results of the present investigation suggest that the "DIVA" control strategy may represent a tool for the control of avian influenza infections in poultry. 相似文献
8.
Ilaria Marigo Luigi Dolcetti Paolo Serafini Paola Zanovello Vincenzo Bronte 《Immunological reviews》2008,222(1):162-179
Summary: Emerging evidence indicates that the Achilles' heel of cancer immunotherapies is often the complex interplay of tumor-derived factors and deviant host properties, which involve a wide range of immune elements in the lymphoid and myeloid compartments. Regulatory lymphocytes, tumor-conditioned myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages, and dysfunctional and immature dendritic cells take part in a complex immunoregulatory network. Despite the fact that some mechanisms governing tumor-induced immune tolerance and suppression are starting to be better understood and their complexity dissected, little is known about the diachronic picture of immune tolerance. Based on observations of MDSCs, we present a time-structured and topologically consistent idea of tumor-dependent tolerance progression in tumor-bearing hosts. 相似文献
9.
Letizia Penolazzi Ilaria Lampronti Monica Borgatti Mahmud Tareq Hassan Khan Margherita Zennaro Roberta Piva Roberto Gambari 《BMC complementary and alternative medicine》2008,8(1):59
Background
Osteoclasts (OCs) are involved in rheumatoid arthritis and in several pathologies associated with bone loss. Recent results support the concept that some medicinal plants and derived natural products are of great interest for developing therapeutic strategies against bone disorders, including rheumatoid arthritis and osteoporosis. In this study we determined whether extracts of Emblica officinalis fruits display activity of possible interest for the treatment of rheumatoid arthritis and osteoporosis by activating programmed cell death of human primary osteoclasts. 相似文献10.